To: AmeriHealth Caritas Louisiana Providers

Date: April 12, 2022

Subject: Updated Clinical Guidelines

Summary: Updated Clinical Guidelines for Magellan/National Imaging Associates.

Content
AmeriHealth Caritas Louisiana would like to make you aware of the updated Magellan/National Imaging Associates clinical guidelines that have been approved by the Louisiana Department of Health in accordance with La. R.S. 46:460.54 and will become effective May 12, 2022. The new guidelines can be found at the following link: https://www1.radmd.com/all-health-plans/amerihealth-caritas-louisiana.aspx [radmd.com].

Guideline Number: NIA_CG_062: CT Coronary Angiography (CCTA)

Questions: Thank you for your continued support and commitment to the care of our members. If you have questions about this communication, please contact AmeriHealth Caritas Louisiana Provider Services at 1-888-922-0007 or your Provider Network Management Account Executive.

Missed an alert?
You can find a complete listing of provider alerts on the Provider Newsletters and Updates page of our website.

Where can I find more information on COVID-19?
AmeriHealth Caritas Louisiana has updated its website to streamline communications and important notifications about COVID-19. Please visit http://amerihealthcaritasla.com/covid-19 for up-to-date information for both providers and members, including frequently asked questions, and important provider alerts from AmeriHealth Caritas Louisiana and the Louisiana Department of Health.
GENERAL INFORMATION
It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

INDICATIONS FOR CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY (CCTA)
(Fihn, 2012; Gulati, 2021; Montalescot, 2013; Taylor, 2010; Wolk, 2014)

Evaluation in Suspected Coronary Artery Disease (CAD)
(Cheng, 2011; Douglas, 2015; Fordyce, 2016; Newby, 2015)

- Intermediate and high pretest probability patients (Gulati, 2021)
- Exercise ECG stress test with intermediate Duke Treadmill Score (-10 to +4)
- Equivocal, borderline, or discordant stress imaging evaluation with continued symptoms concerning for CAD
- Repeat testing in patient with new or worsening symptoms since prior normal stress imaging (Taylor, 2010; Wolk, 2013)
- Asymptomatic patients without known CAD
  - Previously unevaluated ECG evidence of possible myocardial ischemia including ischemic ST segment or T wave abnormalities
  - Previously unevaluated pathologic Q waves
  - Previously unevaluated left bundle branch block
- Newly diagnosed clinical systolic heart failure (ejection fraction [EF] < 50%) or diastolic heart failure without recent CAD evaluation, in the presence of angina or an anginal equivalent
s symptoms, as an alternative to invasive coronary arteriography (Patel, 2012; Patel, 2013; Taylor, 2010; Wolk, 2013)
• Before valve surgery or transcatheter intervention as an alternative to coronary angiography (Baumgartner, 2017; Chaikriangkrai, 2018; Nishimura, 2014)
• To establish the etiology of mitral regurgitation (Nishimura, 2014)
• Evaluation of coronary anomaly or aneurysm (Bluemke, 2008; Grani, 2017; Newburger, 2016; Sachdeva, 2020)
  o Evaluation prior to planned repair
  o Evaluation due to change in clinical status and/or new concerning signs or symptoms
• Evaluation of coronary artery bypass grafts, to assess (Eisenberg, 2017; Taylor, 2010):
  o Patency and location when invasive coronary arteriography was either nondiagnostic or not performed
  o Location prior to cardiac or another chest surgery

BACKGROUND

Coronary computed tomographic angiography (CCTA) is a noninvasive imaging study that uses intravenously administered contrast material and high-resolution, rapid imaging computed tomography (CT) (Nakamura, 2018; Pontone, 2018).

Stable patients without known CAD fall into 2 categories (Fihn, 2012; Montalescot, 2013; Wolk, 2013):
• Asymptomatic, for whom global risk of CAD events can be determined from coronary risk factors, using calculators available online (see Risk Calculators in the Overview section).
• Symptomatic, for whom we estimate the pretest probability that their chest-related symptoms are due to clinically significant CAD.

The Three Types of Chest Pain or Discomfort:

• Typical Angina (Definite) is defined as including all 3 characteristics:
  o Substernal chest pain or discomfort with characteristic quality and duration
  o Provoked by exertion or emotional stress
  o Relieved by rest and/or nitroglycerin
• Atypical Angina (Probable) has only 2 of the above characteristics
• Nonanginal Chest Pain/Discomfort has only 0 - 1 of the above characteristics
• Once the type of chest pain has been established from the medical record, the Pretest Probability of significant CAD is estimated from the Diamond Forrester Table below, recognizing that additional coronary risk factors could increase pretest probability (Wolk, 2013):
<table>
<thead>
<tr>
<th>Age (Years)</th>
<th>Gender</th>
<th>Typical/Definite Angina Pectoris</th>
<th>Atypical/Probable Angina Pectoris</th>
<th>Nonanginal Chest Pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 39</td>
<td>Men</td>
<td>Intermediate</td>
<td>Intermediate</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>Intermediate</td>
<td>Very low</td>
<td>Very low</td>
</tr>
<tr>
<td>40 – 49</td>
<td>Men</td>
<td>High</td>
<td>Intermediate</td>
<td>Intermediate</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>Intermediate</td>
<td>Low</td>
<td>Very low</td>
</tr>
<tr>
<td>50 – 59</td>
<td>Men</td>
<td>High</td>
<td>Intermediate</td>
<td>Intermediate</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>Intermediate</td>
<td>Intermediate</td>
<td>Low</td>
</tr>
<tr>
<td>≥ 60</td>
<td>Men</td>
<td>High</td>
<td>Intermediate</td>
<td>Intermediate</td>
</tr>
<tr>
<td></td>
<td>Women</td>
<td>High</td>
<td>Intermediate</td>
<td>Intermediate</td>
</tr>
</tbody>
</table>

- **Very Low**: < 5% pretest probability of CAD
- **Low**: 5 - 10% pretest probability of CAD
- **Intermediate**: 10% - 90% pretest probability of CAD
- **High**: > 90% pretest probability of CAD

**OVERVIEW**

The 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain has given a Class 1 recommendation with level of evidence of A for patients with stable and acute chest pain, who have no known coronary artery disease (CAD) (Gulati, 2021).

Patient selection and contraindications to CCTA must be considered and may be inappropriate for the following:

- Known history of severe and/or anaphylactic contrast reaction
- Inability to cooperate with scan acquisition and/or breath-hold instructions
- Pregnancy
- Clinical instability (e.g., acute myocardial infarction, decompensated heart failure, severe hypotension)
- Renal impairment as defined by local protocols
- Image quality depends on keeping HR optimally < 60 bpm, a regular rhythm, limited coronary calcification, stents > 3.0 mm in diameter, ≥ 5 second breath hold, and vessels requiring imaging ≥ 1.5 mm diameter (Abbara, 2016).

**Scenarios that can additionally support a CCTA over a regular exercise treadmill test in the low probability scenario**

(Henzlova, 2016)

Inability to Exercise

- Physical limitations precluding ability to exercise for at least 3 full minutes of Bruce protocol
The patient has limited functional capacity (< 4 METS) such as one of the following:
  o Unable to take care of their activities of daily living (ADLs) or ambulate
  o Unable to walk 2 blocks on level ground
  o Unable to climb 1 flight of stairs
  o Unable to vacuum, dust, do dishes, sweep, or carry a small grocery bag

Other Comorbidities
  - Prior cardiac surgery (coronary artery bypass graft or valvular)
  - Left ventricular ejection fraction ≤ 50%
  - Severe chronic obstructive pulmonary disease (COPD) with pulmonary function test (PFT) documentation, severe shortness of breath on minimal exertion, or requirement of home oxygen during the day
  - Poorly controlled hypertension, with systolic blood pressure (BP) > 180 or Diastolic BP > 120

ECG and Echo-Related Baseline Findings
  - Pacemaker or implantable cardioverter defibrillator (ICD)
  - Resting wall motion abnormalities on echocardiography
  - Complete LBBB

Risk-Related
  - Intermediate or high global risk in patients requiring type IC antiarrhythmic drugs
  - Arrhythmia risk with exercise

ECG Stress Test Alone versus Stress Testing with Imaging

Prominent scenarios suitable for an ECG stress test WITHOUT imaging (i.e., exercise treadmill ECG test) require that the patient can exercise for at least 3 minutes of Bruce protocol with achievement of near maximal heart rate AND has an interpretable ECG for ischemia during exercise (Wolk, 2013):
  - The (symptomatic) low pretest probability patient who can exercise and has an interpretable ECG (Wolk, 2014)
  - The patient who is under evaluation for exercise-induced arrhythmia
  - The patient who requires an entrance stress test ECG for a cardiac rehab program or for an exercise prescription
  - For the evaluation of syncope or presyncope during exertion (Shen, 2017)

Duke Exercise ECG Treadmill Score (Mark, 1987)
Calculates risk from ECG treadmill alone:
  - The equation for calculating the Duke treadmill score (DTS) is: DTS = exercise time in minutes - (5 x ST deviation in mm or 0.1 mV increments) - (4 x exercise angina score), with angina score being 0 = none, 1 = non-limiting, and 2 = exercise-limiting
• The score typically ranges from -25 to +15. These values correspond to low-risk (with a score of $\geq +5$), intermediate risk (with scores ranging from -10 to +4), and high-risk (with a score of $\leq -11$) categories.

An uninterpretable baseline ECG includes (Fihn, 2012):
• ST segment depression of 1 mm or more (not for non-specific ST - T wave changes)
• Ischemic looking T wave inversions of at least 2.5 mm
• LVH with repolarization abnormalities, WPW, a ventricular paced rhythm, or left bundle branch block
• Digitalis use with associated ST - T abnormalities
• Resting HR under 50 bpm on a beta blocker and an anticipated suboptimal workload
• Note: RBBB with less than 1 mm ST depression at rest may be suitable for EKG treadmill testing

Global Risk of Cardiovascular Disease

Global risk of CAD is defined as the probability of manifesting cardiovascular disease over the next 10 years and refers to asymptomatic patients without known cardiovascular disease. It should be determined using one of the risk calculators below. A high risk is considered greater than a 20% risk of a cardiovascular event over the ensuing 10 years.

High global risk by itself generally lacks scientific support as an indication for stress imaging (Cheng, 2011).

There are rare exemptions, such as patients requiring IC antiarrhythmic drugs, who might require coronary risk stratification prior to initiation of the drug, when global risk is moderate or high.
• CAD Risk—Low
  10 - year absolute coronary or cardiovascular risk less than 10%
• CAD Risk—Moderate
  10 - year absolute coronary or cardiovascular risk between 10% and 20%
• CAD Risk—High
  10 - year absolute coronary or cardiovascular risk of greater than 20%

Websites for Global Cardiovascular Risk Calculators*
*Patients who have already manifested cardiovascular disease are already at high global risk and are not applicable to the calculators.
(Arnett, 2019; D’Agostino, 2008; Goff, 2014; McClelland, 2015; Ridker, 2007)

<table>
<thead>
<tr>
<th>Risk Calculator</th>
<th>Websites for Online Calculator</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reynolds Risk Score</td>
<td><a href="http://www.reynoldsriskscore.org/">http://www.reynoldsriskscore.org/</a></td>
</tr>
<tr>
<td>Can use if no diabetes</td>
<td></td>
</tr>
<tr>
<td>Unique for use of family history</td>
<td></td>
</tr>
<tr>
<td>Pooled Cohort Equation</td>
<td><a href="http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx?example">http://clincalc.com/Cardiology/ASCVD/PooledCohort.aspx?example</a></td>
</tr>
<tr>
<td>MESA Risk Calculator</td>
<td><a href="https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx">https://www.mesa-nhlbi.org/MESACHDRisk/MesaRiskScore/RiskScore.aspx</a></td>
</tr>
<tr>
<td>With addition of Coronary Artery Calcium Score, for CAD-only risk</td>
<td></td>
</tr>
</tbody>
</table>

**Definitions of Coronary Artery Disease**  
(Fihn, 2012; Lofti, 2018; Mintz, 2016; Montalescot, 2013; Patel, 2017)

- Percentage stenosis refers to the reduction in diameter stenosis when angiography is the method and can be estimated or measured using angiography or more accurately measured with intravascular ultrasound (IVUS).
- Coronary artery calcification is a marker of risk, as measured by Agatston score on coronary artery calcium imaging. It is not a diagnostic tool so much as it is a **risk stratification** tool. Its incorporation into global risk can be achieved by using the MESA risk calculator.
- Stenoses ≥ 70% are considered obstructive coronary artery disease (also referred to as clinically significant), while stenoses ≤ 70% are considered non-obstructive coronary artery disease (Patel, 2017).
- Ischemia-producing disease (also called hemodynamically or functionally significant disease, for which revascularization might be appropriate) generally implies at least one of the following:
  - Suggested by percentage diameter stenosis ≥ 70% by angiography; borderline lesions are 40 - 70% (Fihn, 2012)
  - For a left main artery, suggested by a percentage stenosis ≥ 50% or minimum luminal cross-sectional area on IVUS ≤ 6 square mm (Fihn, 2012; Lofti, 2018; Mintz, 2016)
  - FFR (fractional flow reserve) ≤ 0.80 for a major vessel (Lofti, 2018; Mintz, 2016)
iFR (instantaneous wave-free ratio) ≤ 0.89 for a major vessel (Davies, 2017; Gotberg, 2017; Lofti, 2018)
Demonstrable ischemic findings on stress testing (ECG or stress imaging), that are at least mild in degree

- A major vessel would be a coronary vessel that would be amenable to revascularization, if indicated. This assessment is made based on the diameter of the vessel and/or the extent of myocardial territory served by the vessel.
- FFR is the distal to proximal pressure ratio across a coronary lesion during maximal hyperemia induced by either intravenous or intracoronary adenosine. Less than or equal to 0.80 is considered a significant reduction in coronary flow.
- Newer technology that estimates FFR from CCTA images is covered under the separate NIA Guideline for FFR-CT.

**Anginal Equivalent**
(Fihn, 2012; Moya, 2009; Shen, 2017)

Development of an anginal equivalent (e.g., shortness of breath, fatigue, or weakness) either with or without prior coronary revascularization should be based upon the documentation of reasons that symptoms other than chest discomfort are not due to other organ systems (e.g., dyspnea due to lung disease, fatigue due to anemia), by presentation of clinical data such as respiratory rate, oximetry, lung exam, etc. (as well as d-dimer, chest CT(A), and/or PFTs, when appropriate), and then incorporated into the evaluation of coronary artery disease as would chest discomfort. Syncope per se is not an anginal equivalent.

**Abbreviations**

<table>
<thead>
<tr>
<th>ACS</th>
<th>Acute coronary syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>CABG</td>
<td>Coronary artery bypass grafting surgery</td>
</tr>
<tr>
<td>CAD</td>
<td>Coronary artery disease</td>
</tr>
<tr>
<td>CCS</td>
<td>Coronary calcium score</td>
</tr>
<tr>
<td>CCTA</td>
<td>Coronary computed tomography angiography</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>MI</td>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>MPI</td>
<td>Myocardial Perfusion Imaging</td>
</tr>
<tr>
<td>PCI</td>
<td>Percutaneous coronary intervention</td>
</tr>
<tr>
<td>SE</td>
<td>Stress echocardiography</td>
</tr>
<tr>
<td>TTE</td>
<td>Transthoracic echocardiography</td>
</tr>
</tbody>
</table>
| January 2022 | - Deleted the requirement for stress echocardiography.  
- Changed to Intermediate and High probability chest pain patients now allowable as first line testing  
- Intermediate DTS patients now allowable for CCTA  
- Removed EF < 40%, keeping the existing EF< 50% systolic dysfunction, and adding symptomatic diastolic heart failure with no prior workup  
- Added a paragraph explaining the changes, new guidelines of November 2021 with contraindications within the overview section  
- Added section on when CCTA is preferred over ETT in low-risk patients  
- Deleted the phrasing ‘scenarios that support MPI over SE’ as it would no longer apply here. Replaced with ‘Scenarios that can additionally support a CCTA over a regular exercise treadmill test in the low probability scenario’.  
- Deleted statement that MPI may be supported over CCTA in Poorly controlled atrial fibrillation/ectopy  
- Took out the word ‘intermediate’ in the phrase “The (symptomatic) low pretest probability patient who is able to exercise and has an interpretable ECG”  
- Removed section on Coronary Artery calcium scoring |
| March 2021 | - Deleted: Appropriate exercise ECG stress test with low Duke Treadmill Score (≥ 5) and continued symptoms concerning for CAD  
- Added: High pretest probability as an alternative to coronary angiography (can also do MPI)  
- Removed statement about low Duke treadmill score and continuing symptoms |
| March 2020 | - Added general information section as Introduction which outlines requirements for documentation of pertinent office notes by a licensed clinician, and inclusion of laboratory testing and relevant imaging results for case review  
- Added further details for imaging of coronary anomaly or aneurysm to include the following:  
  o Evaluation prior to planned repair  
  o Evaluation due to change in clinical status and/or new concerning signs or symptoms  
- Added edits to the Coronary Artery Disease definition section  
- Updated and added references |
CCTA can be used as an alternative to coronary angiography in appropriate patients prior to valve surgery or transcatheter intervention.

Noted CMR is favored over CCTA in young patients for evaluation of coronary anomaly or aneurysm.

Global Risk of Cardiovascular Disease information expanded in background section for additional clarification.

REFERENCES:


Cardiology Foundation/American Heart Association Task Force on Practice Guidelines


Reviewed / Approved by NIA Clinical Guideline Committee

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates ("Magellan"). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.